Viewpoint Capital Management’s AbbVie ABBV Stock Holding History

Viewpoint Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$657K	Sell	3,022 -35	-1%	-$7.76K	0.31%	60
2025 Q4	$698K	Hold	3,057	–	–	0.3%	61
2025 Q3	$708K	Hold	3,057	–	–	0.31%	60
2025 Q2	$567K	Hold	3,057	–	–	0.28%	62
2025 Q1	$641K	Hold	3,057	–	–	0.34%	57
2024 Q4	$543K	Hold	3,057	–	–	0.29%	62
2024 Q3	$595K	Hold	3,057	–	–	0.33%	56
2024 Q2	$524K	Hold	3,057	–	–	0.32%	57
2024 Q1	$557K	Sell	3,057 -100	-3%	-$17.2K	0.35%	55
2023 Q4	$489K	Hold	3,157	–	–	0.34%	58
2023 Q3	$471K	Hold	3,157	–	–	0.38%	51
2023 Q2	$425K	Buy	+3,157	New	+$463K	0.33%	59

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viewpoint Capital Management's ABBV Position: Q1 2026 in Review

Viewpoint Capital Management reduced its AbbVie (ABBV) stake by 1.1% in Q1 2026, selling an estimated $7.76K and leaving 3,022 shares worth $657K. The position accounts for 0.31% of the portfolio, ranked #60.

Viewpoint Capital Management first reported a position in ABBV in Q2 2023 and has held it in 12 quarters since. The position peaked at $708K in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Viewpoint Capital Management held 3,022 shares of AbbVie worth $657K as of Q1 2026.
Viewpoint Capital Management sold 35 AbbVie shares in Q1 2026, an estimated $7.76K.
AbbVie made up 0.31% of Viewpoint Capital Management's portfolio in Q1 2026, its #60 holding.
Viewpoint Capital Management first reported a position in AbbVie in Q2 2023 and has held it in 12 quarters since.
Viewpoint Capital Management's AbbVie position peaked at $708K in Q3 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Viewpoint Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.